Medical Breakthrough: Diagnosing Diseases via Breath in Minutes

Medical research is advancing toward non-invasive diagnostic tools that analyze breath molecules to detect diseases, offering an alternative to traditional blood or urine tests. These developments include devices capable of identifying bacterial infections within minutes and portable systems designed to monitor glucose levels and airborne pathogens.

On March 18, 2026, researchers published a study in ACS Central Science detailing a breath test capable of detecting a broad range of bacterial infections in the lungs, blood, muscles, and bone. In tests conducted on mice, the device successfully identified the presence of pathogenic bacteria, including S. Aureus and E. Coli, within 10 minutes.

David M. Wilson, MD, PhD, a professor at the University of California, San Francisco’s department of radiology and biomedical imaging, noted that the development addresses a critical challenge in clinical medicine: the need to quickly distinguish invasive bacterial infections from viral illnesses and noninfectious conditions, especially as antibiotic resistance increases.

The ABLE Device and Airborne Detection

Parallel to bacterial detection research, scientists at the University of Chicago have developed a portable device nicknamed ABLE. According to research published May 21 in Nature Chemical Engineering, the device is four by eight inches across and is designed to capture and detect airborne molecules.

Professor Bozhi Tian, one of the senior authors of the study, indicated that the technology has numerous potential applications. These include the detection of airborne bacteria or viruses in public spaces and hospitals, the improvement of neonatal care, and allowing individuals with diabetes to monitor glucose levels through their breath.

The ABLE system aims to reduce the reliance on liquid-based testing, such as the daily pinpricks required for many people with diabetes or the blood samples typically collected in medical offices.

Broadening the Scope of Breath Analysis

Breath analysis technology is expanding to cover a variety of chronic and acute conditions. A June 25, 2025, report highlighted the development of Ye’s laser-based breathalyzer and the ABLE system’s ability to identify biomarkers for lung cancer, diabetes, and COVID-19.

Beyond acute disease diagnosis, these technologies are being explored for real-time health monitoring. This includes tracking fat-burning levels in athletes to optimize performance and recovery.

research published on March 4, 2026, discussed the implementation of a low-cost, artificial intelligence-powered breath analyzer designed for the early detection of Chronic Obstructive Pulmonary Disease (COPD), a condition responsible for approximately 3.2 million deaths annually.

Technical Foundations and Challenges

The recent bacterial infection test was inspired by existing urea breath tests used to diagnose Helicobacter pylori infections. Those tests function by administering a liquid containing urea molecules tagged with carbon-13; if an infection is present, the bacteria metabolize the urea and release tagged carbon-13 as carbon dioxide, which is then detected in the breath.

While these advancements show promise, several hurdles remain before widespread clinical adoption. Researchers must continue validating specific biomarkers for various diseases and further miniaturize the devices to make them practical for routine use in both clinical and home settings.

Current diagnostic methods for bacterial infections—including imaging, cultures, and blood tests—can be expensive, slow, or non-specific. The goal of these new breath-based technologies is to provide affordable, immediate results to inform urgent treatment decisions.